Navigation Links
In Vitro Safety Screening for Clinical Liabilities, New Life Science Webinar hosted by Xtalks
Date:8/23/2013

Toronto, Canada (PRWEB) August 23, 2013

In vitro pharmacological profiling, testing compounds in select panels of assays like SafetyScreen, play an increasingly important role in reducing drug related safety attrition. In vitro screening identifies off-target activities and their adverse reaction potential by testing compounds for their activity in pharmacologically relevant targets like Serotonin 5H2B, hERG, and others and allows for early risk assessment of compounds. Failure to identify the adverse drug potential of a lead compound may have devastating consequences in later stages of clinical development.

There are several advantages of in vitro profiling; it allows optimizing compounds for specificity and selectivity enables cost effective testing of multiple compounds in parallel, uses species relevant targets and provides fast turnaround times. In vitro screening, when coupled with Pharmaco-Informatics tools can provide valuable information related to potential adverse events, therapeutic applications, repurposing and in vivo efficacy.

Join Dr. Gonzallo Castillo, Technical Director at Eurofins Panlabs, for an informative session. A live Q&A session will follow the main presentation.

To learn more about the event, visit:
http://www.xtalks.com/anti-infective-services-for-drug-discovery.ashx.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/8/prweb11047853.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. In Vitro Diagnostics Market is Expected to Reach USD 74.2 Billion Globally in 2018: Transparency Market Research
2. Hurel Corporation Launches Cell-Based In Vitro Testing Product Suite, Milestone in Movement Away from Use of Live Animals in Drug and Toxicity Testing
3. Marken Meets Critical Demand For In Vitro Lab Shipments
4. Provitro Biosciences Awarded First-Ever U.S. Patent For Large-Scale Production Of Bamboo Plants
5. In Vitro Diagnostics (IVD) - Emerging Countries (Brazil, Russia, India, China) Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
6. Auxogyn And Reproductive Medicine Associates of New Jersey Partner To Advance in vitro fertilization Research
7. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
8. India In Vitro Diagnostics Market Outlook to 2017- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
9. Pittsburgh Based ParentPlus Enters Collaboration with Vitrolife
10. Pharmaceutical and Food Product Safety Made Easier with the Environmental Wireless Validation System by Deadline Solutions, Inc
11. Mucosis Announces Publication of Data Demonstrating Safety and Protection by Mucosally Administered Mimopath®-based Prefusion-like F RSV Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
Breaking Biology News(10 mins):